Back to results
US 2026/0306668 A1Published application
Materials and methods for increasing immune responses within a mammal
AssigneeMayo Foundation for Medical Education and Research
InventorLarry R. Pease
Life of this patent
Estimating the term…
Abstract
This document provides materials and methods for generating activated CAR T cells in vivo. For example, methods of activating naïve T cells in vivo and subsequently engineering at least some of the activated naïve T cells to express a CAR are provided.
Claims21
A method for treating a mammal having cancer, wherein said method comprising:
- (a) administering one or more viral vectors containing nucleic acid encoding an MHC class I molecule or nucleic acid encoding an MHC class II molecule to said mammal to activate a population of naïve T cells within said mammal;
- and
- (b) administering one or more viral vectors containing nucleic acid encoding a heterologous antigen receptor directly into a swollen lymph node within said mammal to generate activated T cells that express said heterologous antigen receptor, wherein said swollen lymph node comprises at least some of said activated naïve T cells.
A method for treating a mammal having cancer, wherein said method comprises:
- (a) administering intradermally one or more viral vectors containing nucleic acid encoding an MHC class I molecule or nucleic acid encoding an MHC class II molecule to said mammal to activate a population of naïve T cells within said mammal;
- and
- (b) administering, one to four days after said step (a), one or more viral vectors containing nucleic acid encoding a heterologous antigen receptor directly into a lymph node downstream of a site of said intradermal administration of said step (a) within said mammal to generate activated T cells that express said heterologous antigen receptor, wherein said lymph node comprises at least some of said activated naïve T cells.
21-23. (canceled)
Dependencies are inferred from the claim text.